These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31649294)

  • 1. BCG instillation versus radical cystectomy for high-risk NMIBC with squamous/glandular histologic variants.
    Suh J; Moon KC; Jung JH; Lee J; Song WH; Kang YJ; Jeong CW; Kwak C; Kim HH; Ku JH
    Sci Rep; 2019 Oct; 9(1):15268. PubMed ID: 31649294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacillus Calmette-Guérin may have clinical benefit for glandular or squamous differentiation in non-muscle invasive bladder cancer patients: retrospective multicenter study.
    Yorozuya W; Nishiyama N; Shindo T; Kyoda Y; Itoh N; Sugita S; Hasegawa T; Masumori N
    Jpn J Clin Oncol; 2018 Jul; 48(7):661-666. PubMed ID: 29733363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome.
    Schubert T; Danzig MR; Kotamarti S; Ghandour RA; Lascano D; Dubow BP; Decastro GJ; Benson MC; McKiernan JM
    World J Urol; 2015 Jun; 33(6):847-52. PubMed ID: 25149472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy.
    Contieri R; Hensley PJ; Tan WS; Grajales V; Bree K; Nogueras-Gonzalez GM; Lee BH; Navai N; Dinney CP; Kamat AM
    Eur Urol Oncol; 2023 Dec; 6(6):590-596. PubMed ID: 37558542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence.
    Abufaraj M; Mostafid H; Shariat SF; Babjuk M
    Curr Opin Urol; 2018 Nov; 28(6):570-576. PubMed ID: 30138122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
    Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
    J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility of Initial Management of High-grade T1 Bladder Cancer With Intravesical BCG vs Immediate Radical Cystectomy.
    Huelster HL; Mason NT; Davaro F; Naqvi SMH; Kim Y; Gilbert SM
    Urology; 2024 May; 187():106-113. PubMed ID: 38467285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology.
    Lone Z; Benidir T; Wood A; Campbell RA; Alaghehbandan R; Li J; Haber GP; Eltemamy M; Haywood SC; Weight CJ; Lee BH; Almassi N
    Urol Oncol; 2024 Mar; 42(3):71.e1-71.e7. PubMed ID: 38135626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
    Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
    J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis.
    Packiam VT; Labbate CV; Boorjian SA; Tarrell R; Cheville JC; Avulova S; Sharma V; Tsivian M; Adamic B; Mahmoud M; Werntz RP; Smith ND; Karnes RJ; Tollefson MK; Steinberg GD; Frank I
    Urol Oncol; 2021 Jul; 39(7):436.e1-436.e8. PubMed ID: 33485764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.